References
- Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018;29(Suppl 4):iv79–iv95.
- Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment – where do we stand? A state of the art review. Cancer Treat. Rev. 2014;40(4):523–532.
- Harrison DJ, Geller DS, Gill JD, et al. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39–50.
- Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?. Eur. J. Cancer. 2011;47(16):2431–2445.
- Li W, Zhang S. Survival of patients with primary osteosarcoma and lung metastases. J Buon. 2018;23:1500–1504.
- Martin E, Senders JT, Ter Wengel PV, et al. Treatment and survival of osteosarcoma and Ewing sarcoma of the skull: a SEER database analysis. Acta Neurochir. 2019;161(2):317–325.
- Jain M, Nilsson R, Sharma S, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336(6084):1040–1044.
- Zheng Y, Lin TY, Lee G, et al. Mitochondrial one-carbon pathway supports cytosolic folate integrity in cancer cells. Cell. 2018;175(6):1546–1560.e1517.
- Lee D, Xu IM, Chiu DK, et al. Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. J Clin Invest. 2017;127(5):1856–1872.
- Pike ST, Rajendra R, Artzt K, et al. Mitochondrial C1-tetrahydrofolate synthase (MTHFD1L) supports the flow of mitochondrial one-carbon units into the methyl cycle in embryos. J Biol Chem. 2010;285(7):4612–4620.
- Agarwal S, Behring M, Hale K, et al. MTHFD1L, a folate cycle enzyme, is involved in progression of colorectal cancer. Transl Oncol. 2019;12(11):1461–1467.
- Li H, Fu X, Yao F, et al. MTHFD1L-mediated redox homeostasis promotes tumor progression in tongue squamous cell carcinoma. Front Oncol. 2019;9:1278–1278.
- Raymond AK, Jaffe N. Osteosarcoma multidisciplinary approach to the management from the pathologist’s perspective. Cancer Treat Res. 2009;152:63–84.
- Asante I, Chui D, Pei H, et al. Alterations in folate-dependent one-carbon metabolism as colon cell transition from normal to cancerous. J. Nutr. Biochem. 2019;69:1–9.
- Yang Y-S, Yuan Y, Hu W-P, et al. The role of mitochondrial folate enzyme MTHFD1L in esophageal squamous cell carcinoma. Scand J Gastroenterol. 2018;53(5):533–540.
- Ding K, Jiang J, Chen L, et al. Methylenetetrahydrofolate dehydrogenase 1 silencing expedites the apoptosis of non-small cell lung cancer cells via modulating DNA methylation. Med Sci Monit. 2018;24:7499–7507.
- Tchakarska G, Sola B. The double dealing of cyclin D1. Cell Cycle (Georgetown, Tex.). 2020;19(2):163–178.
- Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature. 1991;349(6305):132–138.
- Xu J, Huang F, Yao Z, et al. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Cell Commun Signal. 2019;17(1):85–85.
- Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA. 2014;111(51):E5564–E5573.
- Ma H, Su R, Feng H, et al. Long noncoding RNA UCA1 promotes osteosarcoma metastasis through CREB1-mediated epithelial-mesenchymal transition and activating PI3K/AKT/mTOR pathway. J Bone Oncol. 2019;16:100228–100228.
- Zhao G-S, Gao Z-R, Zhang Q, et al. TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis. J Exp Clin Cancer Res. 2018;37(1):188–188.
- Jin R, Jin Y-Y, Tang Y-L, et al. GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway. Oncol Rep. 2018;39(6):3034–3040.